期刊
ONCOGENE
卷 29, 期 37, 页码 5120-5134出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2010.273
关键词
drug resistance; AML; FLT3; combination therapy; stroma
资金
- National Institutes of Health [CA134660-02, CA36167, DK50654]
- Leukemia and Lymphoma Society
- NATIONAL CANCER INSTITUTE [R37CA036167, R01CA134660, R01CA036167] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050654] Funding Source: NIH RePORTER
Mutant Fms-Like Tyrosine kinase-3 (FLT3), which is expressed in the leukemic cells of a subpopulation of acute myeloid leukemia (AML) patients, represents an attractive target for the therapy of AML. There are several FLT3 inhibitors presently in clinical trials with sufficient efficacy and toxicity features to warrant further testing in combination with standard therapies. However, the transient and partial responses observed in AML patients treated with FLT3 inhibitors, coupled with the discovery of drug-resistant leukemic blast cells in AML patients, have made resistance to FLT3 inhibitors a growing concern. In this study, we provide an overview of the role of mutant FLT3 in AML, FLT3 inhibitors under clinical and preclinical investigation, mechanisms of resistance to FLT3 inhibitors, and possible therapeutic approaches to overcoming this resistance. Oncogene (2010) 29, 5120-5134; doi:10.1038/onc.2010.273; published online 12 July 2010
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据